Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its products portfolio includes Pantoprazole Sodium Enteric-coated, Ferrous Succinate, Rosuvastatin Calcium, Ebastine, and Rabeprazole Sodium Enteric-coated Tablets; and Acetylcysteine Granules, Potassium Sodium Hydrogen Citrate Granules, Loxoprofen Sodium Gel Pat… Read more
Hunan Jiudian Pharmaceutical Co Ltd (300705) - Total Assets
Latest total assets as of September 2025: CN¥3.67 Billion CNY
Based on the latest financial reports, Hunan Jiudian Pharmaceutical Co Ltd (300705) holds total assets worth CN¥3.67 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hunan Jiudian Pharmaceutical Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Hunan Jiudian Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hunan Jiudian Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hunan Jiudian Pharmaceutical Co Ltd's total assets of CN¥3.67 Billion consist of 47.5% current assets and 52.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.1% |
| Accounts Receivable | CN¥476.80 Million | 14.1% |
| Inventory | CN¥367.70 Million | 10.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥150.11 Million | 4.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Hunan Jiudian Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hunan Jiudian Pharmaceutical Co Ltd's current assets represent 47.5% of total assets in 2024, a decrease from 57.3% in 2013.
- Cash Position: Cash and equivalents constituted 13.1% of total assets in 2024, down from 17.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 9.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 14.1% of total assets.
Hunan Jiudian Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Hunan Jiudian Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Hunan Jiudian Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Hunan Jiudian Pharmaceutical Co Ltd generates 0.87x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Hunan Jiudian Pharmaceutical Co Ltd generates $ 15.19 in net profit.
Hunan Jiudian Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.81 | 4.23 | 2.78 |
| Quick Ratio | 3.60 | 3.35 | 1.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.25 Billion | CN¥ 1.22 Billion | CN¥ 322.64 Million |
Hunan Jiudian Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hunan Jiudian Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.92 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | 17.5% |
| Total Assets | CN¥3.37 Billion |
| Market Capitalization | $528.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hunan Jiudian Pharmaceutical Co Ltd's assets below their book value (0.16 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Hunan Jiudian Pharmaceutical Co Ltd's assets grew by 17.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hunan Jiudian Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total assets of Hunan Jiudian Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.37 Billion | +17.48% |
| 2023-12-31 | CN¥2.87 Billion | +24.85% |
| 2022-12-31 | CN¥2.30 Billion | +31.77% |
| 2021-12-31 | CN¥1.75 Billion | +54.35% |
| 2020-12-31 | CN¥1.13 Billion | +5.47% |
| 2019-12-31 | CN¥1.07 Billion | +13.66% |
| 2018-12-31 | CN¥943.21 Million | +22.62% |
| 2017-12-31 | CN¥769.20 Million | +93.74% |
| 2016-12-31 | CN¥397.03 Million | +24.73% |
| 2015-12-31 | CN¥318.32 Million | +18.52% |
| 2014-12-31 | CN¥268.57 Million | +6.51% |
| 2013-12-31 | CN¥252.15 Million | -- |